Corcept Therapeutics (CORT) Gross Profit (2012 - 2026)
Corcept Therapeutics (CORT) posted Gross Profit of $252.1 million for Q2 2026, up 55.59% sequentially from $162.0 million in Q1 2026, and up 31.98% YoY from $191.0 million in Q2 2025.
Corcept Therapeutics (CORT) Gross Profit (2012 - 2026) Analysis & Trends
Corcept Therapeutics has reported Gross Profit for 15 years, with the latest figure at $252.1 million in Q2 2026.
- Quarterly Gross Profit rose 31.98% year-over-year to $252.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $816.7 million (up 15.94% YoY) and the FY2025 annual result came in at $748.4 million, up 12.69% from the prior year.
- Gross Profit improved to $252.1 million in Q2 2026 per CORT's latest filing, from $162.0 million in the prior quarter.
- Over five years, Gross Profit peaked at $252.1 million in Q2 2026 and troughed at $92.4 million in Q1 2022.
- A 5-year average of $149.9 million and a median of $149.5 million in 2024 frame the typical range for Gross Profit.
- The sharpest annual moves came in 2022 and 2024: Gross Profit climbed 4.21% in 2022, then jumped 47.33% in 2024.
- Over 5 years, Gross Profit stood at $101.6 million in 2022, then jumped by 31.46% to $133.5 million in 2023, then surged by 34.0% to $178.9 million in 2024, then increased by 11.54% to $199.6 million in 2025, then grew by 26.31% to $252.1 million in 2026.
- According to Business Quant data, Gross Profit over the past three periods registered $252.1 million, $162.0 million, and $199.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 252.09 Mn |
| Jun 30, 2026 | 252.09 Mn |
| Mar 31, 2026 | 162.02 Mn |
| Mar 31, 2026 | 162.02 Mn |
| Dec 31, 2025 | 199.58 Mn |
| Dec 31, 2025 | 199.58 Mn |
| Sep 30, 2025 | 203.04 Mn |
| Sep 30, 2025 | 203.04 Mn |
| Jun 30, 2025 | 191.00 Mn |
| Jun 30, 2025 | 191.00 Mn |
| Mar 31, 2025 | 154.81 Mn |
| Mar 31, 2025 | 154.81 Mn |
| Dec 31, 2024 | 178.93 Mn |
| Dec 31, 2024 | 178.93 Mn |
| Sep 30, 2024 | 179.68 Mn |
| Sep 30, 2024 | 179.68 Mn |
| Jun 30, 2024 | 161.27 Mn |
| Jun 30, 2024 | 161.27 Mn |
| Mar 31, 2024 | 144.27 Mn |
| Mar 31, 2024 | 144.27 Mn |